Following Guillain-Barré syndrome (GBS),
expectation for ANX007 in geographic atrophy(GA) .
Phase3TLD:2026-2H
Primary Completion (Estimated) 2026-10-31
NCT06510816
cf. competitor in GA
・Belite Bio(Tinlarebant / LBS‑008)
NCT05949593
・Boehringer Ingelheim(BI1584862)
NCT06769048
投資の参考になりましたか?

